Equities analysts expect Aerpio Pharmaceuticals, Inc. (NYSE:ARPO) to announce earnings per share (EPS) of ($0.12) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Aerpio Pharmaceuticals’ earnings. Aerpio Pharmaceuticals reported earnings per share of ($0.21) in the same quarter last year, which would indicate a positive year-over-year growth rate of 42.9%. The company is expected to announce its next earnings report on Tuesday, March 3rd.
According to Zacks, analysts expect that Aerpio Pharmaceuticals will report full-year earnings of ($0.53) per share for the current year, with EPS estimates ranging from ($0.60) to ($0.46). For the next fiscal year, analysts expect that the company will post earnings of ($0.34) per share, with EPS estimates ranging from ($0.46) to ($0.21). Zacks’ earnings per share averages are an average based on a survey of analysts that cover Aerpio Pharmaceuticals.
NYSE ARPO traded down $0.03 during trading on Friday, hitting $0.56. The company had a trading volume of 168,904 shares, compared to its average volume of 250,169. The company’s fifty day moving average is $0.54 and its 200-day moving average is $0.73. Aerpio Pharmaceuticals has a one year low of $0.45 and a one year high of $4.25.
Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy.
Further Reading: Current Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.